Progressive loss of sensitivity to endothelium‐derived growth inhibitors expressed by human melanoma cells during disease progression

Tumor progression is frequently associated with changes in responsiveness of tumor cells to paracrine growth factors. A potential major source of such paracrine factors in solid tumors are endothelial cells since this type of cell can constitute a sizeable fraction of the cellular composition of solid tumors. As an initial step to examining the possible effects of endothelial cell‐associated growth factors on tumor cell growth, a panel of human melanoma cell lines representative of different stages of tumor progression was employed for studies utilizing endothelial cell‐derived growth modulators. Macrovascular or microvascular human endothelial cells from umbilical vein or from skin, respectively, inhibited melanoma cell growth in direct coculture experiments. The potency of this inhibitory effect diminished as a function of melanoma progression. Conditioned media from endothelial cell cultures mimicked the effect of the cell coculture experiments, suggesting the involvement of soluble growth factor(s). Approximately 50–75% of the conditioned media inhibitory effect was abrogated by addition of the neutralizing antibody to interleukin‐6 (IL‐6). Gel filtration chromatography revealed the presence of additional inhibitors in endothelial cell conditioned medium. Two peaks of activity were detected with apparent molecular weights of approximately 100–150 Kd and 20–30 Kd, the latter containing IL‐6 activity. Whereas early‐stage radial growth phase (RGP) primary tumor‐derived melanoma cells were sensitive to at least three different endothelial products of high or low molecular weight (including IL‐6), melanoma cells from more advanced metastatic lesions were resistant to the latter activities, and retained only partial sensitivity to the high molecular weight inhibitor. More advanced vertical growth phase (VGP) primary melanoma cell lines expressed intermediate inhibition‐sensitive phenotypes. Thus human melanoma development appears to be associated with progressive loss of sensitivity to the growth inhibitory effects of IL‐6 and other factors produced by endothelial cells. This is likely to be a result of a selection process when tumor cells are confronted with adjacent vasculature during the progress of tumor angiogenesis. © 1994 wiley‐Liss, Inc.

[1]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[2]  R. Barnhill,et al.  Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis. , 1993, The American journal of pathology.

[3]  R. Kerbel,et al.  Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions. , 1993, Cancer research.

[4]  R. Kerbel,et al.  Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression [published erratum appears in J Cell Biol 1993 Apr;121(2):following 477] , 1993, The Journal of cell biology.

[5]  R. Strieter,et al.  Interleukin-8 as a macrophage-derived mediator of angiogenesis. , 1992, Science.

[6]  R. Kerbel,et al.  Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Kerbel Rs Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. , 1992 .

[8]  C. Kirkpatrick,et al.  Interaction of human malignant melanoma (ST-ML-12) tumor spheroids with endothelial cell monolayers. Damage to endothelium by oxygen-derived free radicals. , 1992, The American journal of pathology.

[9]  G. Nicolson,et al.  Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. , 1992, British Journal of Cancer.

[10]  I. Macdonald,et al.  Early steps in hematogenous metastasis of B16F1 melanoma cells in chick embryos studied by high-resolution intravital videomicroscopy. , 1992, Journal of the National Cancer Institute.

[11]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[12]  C. Figdor,et al.  Differential cytostatic activity of monocyte‐derived cytokines against human melanoma cells , 1992, International journal of cancer.

[13]  R. Hamanaka,et al.  Endogenous basic fibroblast growth factor-dependent induction of collagenase and interleukin-6 in tumor necrosis factor-treated human microvascular endothelial cells. , 1991, The Journal of biological chemistry.

[14]  J. Liu,et al.  Regulation of IL-6 expression by oncostatin M. , 1991, Journal of immunology.

[15]  W. Clark,et al.  Biomarkers for individual susceptibility to carcinogenic agents: excretion and carcinogenic risk of benzo[a]pyrene metabolites. , 1992, Environmental health perspectives.

[16]  F. Burrows,et al.  Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro. , 1991, Cancer research.

[17]  G. Cunha,et al.  Mesenchyme-induced changes in the neoplastic characteristics of the Dunning prostatic adenocarcinoma. , 1991, Cancer research.

[18]  N. Rosen,et al.  Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. , 1991, Cancer research.

[19]  R. Kerbel,et al.  Reduction of TGF‐beta activity abrogates growth promoting tumor cell‐cell interactions in vivo , 1991, Journal of cellular physiology.

[20]  M. Herlyn,et al.  Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[21]  F. Orr,et al.  Endothelial cell damage by Walker carcinosarcoma cells is dependent on vitronectin receptor-mediated tumor cell adhesion. , 1991, The American journal of pathology.

[22]  F. Blasi,et al.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.

[23]  M. Nagao,et al.  A fibroblast-derived tumor cytotoxic factor/F-TCF (hepatocyte growth factor/HGF) has multiple functions in vitro. , 1991, Cell biology international reports.

[24]  F. Herrmann,et al.  Expression of leukemia inhibitory factor is regulated in human mesenchymal cells. , 1991, Leukemia.

[25]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[26]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[27]  P. Sehgal Interleukin 6 in Infection and Cancer , 1990, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[28]  W. Buurman,et al.  IFN-gamma regulates the expression of the adhesion molecule ELAM-1 and IL-6 production by human endothelial cells in vitro. , 1990, Journal of immunology.

[29]  B. Zetter,et al.  Tumor interactions with the vasculature: angiogenesis and tumor metastasis. , 1990, Biochimica et biophysica acta.

[30]  L. Sachs,et al.  Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Sehgal,et al.  Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells , 1989, The Journal of experimental medicine.

[32]  R. Hofmann-Wellenhof,et al.  Vascular architecture of melanocytic skin tumors. A quantitative immunohistochemical study using automated image analysis. , 1989, Pathology, research and practice.

[33]  E. Wagner,et al.  Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment , 1989, Cell.

[34]  Sandra R. Smith,et al.  An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Derynck,et al.  Expression and secretion of gro/MGSA by stimulated human endothelial cells. , 1989, The EMBO journal.

[36]  S. Tatter,et al.  Multiple forms of IFN-beta 2/IL-6 in serum and body fluids during acute bacterial infection. , 1989, Journal of immunology.

[37]  A. Srivastava,et al.  Vascularity in cutaneous melanoma detected by Doppler sonography and histology: correlation with tumour behaviour. , 1989, British Journal of Cancer.

[38]  A. Srivastava,et al.  The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. , 1988, The American journal of pathology.

[39]  B. Kwon,et al.  bFGF as an autocrine growth factor for human melanomas. , 1988, Oncogene research.

[40]  R. Auerbach,et al.  Tumor cells are protected from NK‐cell‐mediated lysis by adhesion to endothelial cells , 1988, International journal of cancer.

[41]  D. Pleskow,et al.  Latent transformed growth-inhibiting factor in human malignant effusions. , 1988, Cancer research.

[42]  J. Folkman What is the role of angiogenesis in metastasis from cutaneous melanoma? , 1987, European journal of cancer & clinical oncology.

[43]  E. Pardon,et al.  Specificity of adhesion between murine tumor cells and capillary endothelium: an in vitro correlate of preferential metastasis in vivo. , 1987, Cancer research.

[44]  Y. Kitano,et al.  Separation of the epidermal sheet by dispase , 1983, The British journal of dermatology.

[45]  E. Rofstad,et al.  Vascular structure of five human malignant melanomas grown in athymic nude mice. , 1982, British Journal of Cancer.

[46]  R. Kerbel,et al.  The Role of Angiogenesis in Tumor Progression and Metastasis , 1993 .

[47]  T. Børsum Biochemical properties of vascular endothelial cells , 1991, Virchows Archiv. B, Cell pathology including molecular pathology.

[48]  G. Nicolson,et al.  Direct in vitro lysis of metastatic tumor cells by cytokine-activated murine vascular endothelial cells. , 1991, Cancer research.

[49]  A. van den Hooff,et al.  Stromal involvement in malignant growth. , 1988 .